Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, announced the successful closing of an $8 million Series A financing round. The funding round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund.
Since its founding in 2023, Infinity Bio has established a 9,000 square-foot laboratory in Baltimore and developed a suite of core services, including HuSIGHT, VirSIGHT, AllerSIGHT, and MuSIGHT, designed to support applications in biomarker discovery, basic and translational research, and therapeutic development. And the company’s platform is capable of processing thousands of samples per week, serving academic, government, and biopharma customers.
Acquisition of Serimmune: As part of the plan to broaden its suite of service offerings, Infinity Bio acquired the assets of Serimmune, which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA service offerings, including EnviroSIGHT, are also expected to launch in the second half of 2025.
How the funding will be used: Infinity Bio will use the proceeds to expand its commercial footprint, accelerate development of its proprietary MIPSA platform, and launch new immune profiling services. The platform enables unbiased, high-resolution analysis of the antibody reactome, an emerging field critical to understanding immune responses in health and disease.
KEY QUOTES:
“This raise marks a major milestone for Infinity Bio. We are building the foundation for a new category of immune system intelligence: accessible, scalable, and deeply informative. With support from our investors, we can now move faster to deliver that vision.”
Joy Nassif, Chief Executive Officer of the company
“True to our name, Infinity Bio is building a limitless capacity to generate high quality antibody reactome data and deliver valuable biological insights for just about any kind of study. Our technologies illuminate the complex interplay between inflammation, immunity, and health.”
Ben Larman, Chief Science Officer of Infinity Bio, and associate professor of pathology at Johns Hopkins University
“We applaud the scientific prowess of Infinity Bio to provide insights into the immune system through its antibody reactome profiling platform. Combined with the assets from Serimmune, this enhanced, more comprehensive technology is a game changer for biomedical researchers who can use it for a broad range of applications to accelerate their discoveries.”
Malek Faham, MD, PhD, Chief Scientist at Illumina Ventures
“We launched Infinity Bio with global ambition to unlock a new layer of immune system data that drives better diagnostics, targeted therapies, and deeper disease insight. Partnering with a world-class firm like Illumina Ventures reinforces that vision and positions Infinity to scale as the category leader in antibody reactome profiling.”
Matt Hellauer, Managing Partner at PTX Capital and Chairman of Infinity Bio
